The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E - PubMed (original) (raw)
. 1980 Nov 10;255(21):10464-71.
- PMID: 6253476
Free article
The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E
E E Windler et al. J Biol Chem. 1980.
Free article
Abstract
Hepatic catabolism of lipoproteins containing apolipoproteins B or E is enhanced in rats treated with pharmacologic doses of 17 alpha-ethinyl estradiol. Liver membranes prepared from these rats exhibit an increased number of receptor sites that bind 125I-labeled human low density lipoproteins (LDL) in vitro. In the present studies, this estradiol-stimulated hepatic receptor was shown to recognize the following rat lipoproteins: LDL, very low density lipoproteins obtained from liver perfusates (hepatic VLDL), and VLDL-remnants prepared by intravenous injection of hepatic VLDL into functionally eviscerated rats. The receptor also recognized synthetic lamellar complexes of lecithin and rat apoprotein E as well as canine high density lipoproteins containing apoprotein E (apo E-HDLc). It did not recognize human HDL or rat HDL deficient in apoprotein E. Much smaller amounts of this high affinity binding site were also found on liver membranes from untreated rats, the number of such sites increasing more than 10-fold after the animals were treated with estradiol. Each of the rat lipoproteins recognized by this receptor was taken up more rapidly by perfused livers from estrogen-treated rats. In addition, enrichment of hepatic VLDL with C-apoproteins lowered the ability of these lipoproteins to bind to the estradiol-stimulated receptor and diminished their rate of uptake by the perfused liver of estrogen-treated rats, just as it did in normal rats. The current data indicate that under the influence of pharmacologic doses of estradiol the liver of the rat contains increased amounts of a functional lipoprotein receptor that binds lipoproteins containing apoproteins B and E. This hepatic lipoprotein receptor appears to mediate the uptake and degradation of lipoproteins by the normal liver as well as the liver of estradiol-treated rats. The hepatic receptor bears a close functional resemblance to the LDL receptor previously characterized on extrahepatic cells.
Similar articles
- Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.
Hui DY, Innerarity TL, Mahley RW. Hui DY, et al. J Biol Chem. 1981 Jun 10;256(11):5646-55. J Biol Chem. 1981. PMID: 6263887 - Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.
Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW. Schneider WJ, et al. J Clin Invest. 1981 Oct;68(4):1075-85. doi: 10.1172/jci110330. J Clin Invest. 1981. PMID: 6270194 Free PMC article. - Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism.
Havel RJ, Hamilton RL. Havel RJ, et al. Hepatology. 1988 Nov-Dec;8(6):1689-704. doi: 10.1002/hep.1840080637. Hepatology. 1988. PMID: 2847970 Review. - The role of lipoprotein receptors in lipid transport and in the pathogenesis of the hyperlipoproteinemias.
Chait A. Chait A. Spec Top Endocrinol Metab. 1983;5:1-53. Spec Top Endocrinol Metab. 1983. PMID: 6322371 Review.
Cited by
- A sexually dimorphic hepatic cycle of periportal VLDL generation and subsequent pericentral VLDLR-mediated re-uptake.
Martini T, Gobet C, Salati A, Blanc J, Mookhoek A, Reinehr M, Knott G, Sordet-Dessimoz J, Naef F. Martini T, et al. Nat Commun. 2024 Sep 28;15(1):8422. doi: 10.1038/s41467-024-52751-2. Nat Commun. 2024. PMID: 39341814 Free PMC article. - The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles.
Cui Q, Jeyachandran AV, Garcia G, Qin C, Zhou Y, Zhang M, Wang C, Sun G, Liu W, Zhou T, Feng L, Palmer C, Li Z, Aziz A, Gomperts BN, Feng P, Arumugaswami V, Shi Y. Cui Q, et al. MedComm (2020). 2023 Oct 10;4(5):e400. doi: 10.1002/mco2.400. eCollection 2023 Oct. MedComm (2020). 2023. PMID: 37822714 Free PMC article. - High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes.
Németh K, Tóth B, Sarnyai F, Koncz A, Lenzinger D, Kereszturi É, Visnovitz T, Kestecher BM, Osteikoetxea X, Csala M, Buzás EI, Tamási V. Németh K, et al. Nutr Metab (Lond). 2023 Mar 31;20(1):19. doi: 10.1186/s12986-023-00738-z. Nutr Metab (Lond). 2023. PMID: 37004042 Free PMC article. - Effects of bazedoxifene and low-intensity aerobic exercise on bone and fat parameters in ovariectomized rats.
Yuasa Y, Miyakoshi N, Kasukawa Y, Nagahata I, Akagawa M, Ono Y, Sato C, Tsuchie H, Nozaka K, Nagasawa H, Hongo M, Shimada Y. Yuasa Y, et al. J Bone Miner Metab. 2020 Mar;38(2):179-187. doi: 10.1007/s00774-019-01045-5. Epub 2019 Oct 5. J Bone Miner Metab. 2020. PMID: 31587108 - Menopausal Status and Physical Activity Are Independently Associated With Cardiovascular Risk Factors of Healthy Middle-Aged Women: Cross-Sectional and Longitudinal Evidence.
Karvinen S, Jergenson MJ, Hyvärinen M, Aukee P, Tammelin T, Sipilä S, Kovanen V, Kujala UM, Laakkonen EK. Karvinen S, et al. Front Endocrinol (Lausanne). 2019 Aug 30;10:589. doi: 10.3389/fendo.2019.00589. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31543865 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources